REFRACTORY ACUTE MYELOID LEUKEMIA

This early-stage trial tests a new drug (8-chloro-adenosine) combined with an existing drug (venetoclax) in 30 adults whose acute myeloid leukemia has come back or stopped responding to standard treatments. The main goal is to find the safest dose and check for side effects. The …

This study tests a combination of two chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in about 50 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment, or with high-risk myelodysplastic syndrome (MDS). The goal is to see if the combinati…

This early-stage trial tested whether adding regorafenib to the standard venetoclax and azacitidine regimen is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study aimed to find the best dose and check fo…

This early-phase trial tests the safety and best dose of two drugs, selinexor and venetoclax, when added to standard chemotherapy for children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. The study involves 37 participants and ai…

This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in adults whose cancer has returned or not responded to prior treatment, as well as in older adults newly diagnosed who cannot tolerate strong chemotherapy. About 85 participa…

This early-phase study tests a new drug called M3814 combined with three chemotherapy drugs (MEC) in 48 adults whose acute myeloid leukemia has returned or not responded to prior treatment. The main goal is to find the safest dose and understand side effects. Researchers hope thi…

This study tests a combination of two drugs, venetoclax and decitabine, in 20 adults with acute myeloid leukemia that has returned or not responded to prior treatment. The goal is to see if the combination can shrink or control the cancer. Participants will receive the drugs oral…

This study tests a new combination of two drugs, nintedanib and azacitidine, in older adults with acute myeloid leukemia (AML) who cannot have or do not want standard intensive chemotherapy. The goal is to find the best dose of nintedanib when given with azacitidine and to see wh…

This early-phase trial tests a drug called flotetuzumab in children, teens, and young adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The drug works by helping the immune system attack leukemia cells. The main goals are to find the s…

This study tests adding the targeted drug sorafenib to standard chemotherapy (busulfan and fludarabine) before a donor stem cell transplant for people with acute myeloid leukemia (AML) that has returned or not responded to treatment. The goal is to find the safest dose of sorafen…

This early-phase trial tests a new drug (navtemadlin) combined with two standard drugs (decitabine and venetoclax) in adults with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to find the safest dose and check for side effects. About …

This early-stage study tests a new type of immunotherapy for people with certain leukemias that have come back or not responded to standard treatment. The therapy uses a patient's own or donor's immune cells that are genetically modified to recognize and attack cancer cells carry…

This early-stage trial tests a drug called palbociclib, alone or with other medicines, in people with leukemia that has returned or not responded to prior therapy. The main goal is to find the safest dose and understand side effects. About 32 adults aged 15 and older with acute m…

This early-stage trial tests a new drug called TAK-243 in about 42 adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or stopped responding to standard therapy. The main goals are to find the best dose and check for side effects. TAK-243 works by blockin…

This study tested whether adding the drug veliparib to standard chemotherapy helps people with advanced blood cancers like acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). About 25 adults took part. The goal was to see if the combination improved response …

This study looks at a drug called enasidenib for children and teens with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. Only patients with a specific genetic change (IDH2 mutation) are included. The goal is to check the drug's safety and ho…

This study tests a drug called olaparib in 14 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to treatment, and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to g…

This early-stage study tests a new three-drug combination for people with acute myeloid leukemia (AML) that has returned or stopped responding to standard treatments, including the drug venetoclax. The main goal is to find the safest dose and understand side effects. About 17 adu…

This study tests a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 people with Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia that has worsened. The goal is to see how well the drugs work together to control the ca…

This early-stage study tests a combination of two drugs—ipilimumab, which boosts the immune system to attack cancer, and decitabine, a chemotherapy drug—in people whose myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has returned or not responded to prior treatment…

This early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…

This early-stage trial tests a combination of two drugs—entrectinib and ASTX727—in adults with acute myeloid leukemia (AML) that has returned or not responded to treatment and has a specific genetic change (TP53 mutation). The goal is to find the safest dose and see if the combin…